- Home
- INDP vs KTTA Comparison
INDP vs KTTA Comparison
Compare INDP & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INDP
- KTTA
- Stock Information
- Founded
- INDP 2000
- KTTA 2020
- Country
- INDP United States
- KTTA United States
- Employees
- INDP N/A
- KTTA N/A
- Industry
- INDP Biotechnology: Pharmaceutical Preparations
- KTTA Biotechnology: Pharmaceutical Preparations
- Sector
- INDP Health Care
- KTTA Health Care
- Exchange
- INDP Nasdaq
- KTTA Nasdaq
- Market Cap
- INDP 6.0M
- KTTA 5.1M
- IPO Year
- INDP N/A
- KTTA 2021
- Fundamental
- Price
- INDP $2.40
- KTTA $0.78
- Analyst Decision
- INDP Strong Buy
- KTTA
- Analyst Count
- INDP 2
- KTTA 0
- Target Price
- INDP $238.00
- KTTA N/A
- AVG Volume (30 Days)
- INDP 77.0K
- KTTA 184.2K
- Earning Date
- INDP 08-13-2025
- KTTA 08-14-2025
- Dividend Yield
- INDP N/A
- KTTA N/A
- EPS Growth
- INDP N/A
- KTTA N/A
- EPS
- INDP N/A
- KTTA N/A
- Revenue
- INDP N/A
- KTTA N/A
- Revenue This Year
- INDP N/A
- KTTA N/A
- Revenue Next Year
- INDP N/A
- KTTA N/A
- P/E Ratio
- INDP N/A
- KTTA N/A
- Revenue Growth
- INDP N/A
- KTTA N/A
- 52 Week Low
- INDP $2.47
- KTTA $0.65
- 52 Week High
- INDP $58.24
- KTTA $7.50
- Technical
- Relative Strength Index (RSI)
- INDP 18.11
- KTTA 53.64
- Support Level
- INDP $6.26
- KTTA $0.74
- Resistance Level
- INDP $6.65
- KTTA $0.81
- Average True Range (ATR)
- INDP 0.69
- KTTA 0.06
- MACD
- INDP -0.33
- KTTA -0.00
- Stochastic Oscillator
- INDP 1.86
- KTTA 42.95
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).